UK stocks open 1.1% lower as trade tensions escalate
Source - SMW
UK stocks opened substantially lower on Monday after oil and mining stocks were hurt by growing fears about the health of US trade relationships with China and Mexico.
At 0848, the FTSE 100 was down 80.28 points, or 1.1%, at 7.082.24.
BP, Shell, BHP and Rio Tinto fell 1.4%, 1.6%, 1.6% and 1.2%, respectively.
Construction company Kier plugned 38% after it warned on profits, citing slowing sales growth.
Telecom services provider KCOM jumped 13% after it withdrew its support for a takeover bid from Universities Superannuation Scheme in favour of a superior £563m offer from Macquarie Infrastructure and Real Assets.
Funerals company Dignity fell 4.4% after the UK government tightened regulation in the funeral sector. The company said it had been calling on change for years, arguing that it would help crack down on poor sales practices by some rivals.
AstraZeneca fell 1.1% despite it and partner Merck recording positive results from a pancreatic cancer treatment trial.
Bonding solutions supplier Scapa tumbled 46% after key customer ConvaTec moved to terminate a master supply agreement with the company. Scapa said it would contest the termination.
Iron deficiency focused Shield Therapeutics dropped 14% on news that that Teva Pharmaceutical Industries had filed a notice of appeal regarding a previous patent ruling.
Financial services group Tatton Asset Management rallied 6.4% as it booked a rise in annual profit after it boosted its funds under management. The company also announced a contract win with Tenet Group.
Mass spectrometry instrument developer Microsaic Systems jumped 16% after it announced that it had developed proof of concept for a new technology that could slash customer costs.
Specialist engineer TP Group gained 5.7% on announcing that it had entered into a nine-year exclusive licensing agreement with Batelle to be a technology partner for their nanotechnology material.
Proton therapy system developer Advanced Oncotherapy advanced 1.1% amid the generation of positive study results demonstrating the performance of its proprietary proton accelerator.